| Literature DB >> 35990357 |
Saikat Mitra1, Talha Bin Emran2,3, Deepak Chandran4, B M Redwan Matin Zidan1, Rajib Das1, Sukamto S Mamada5, Ayu Masyita5, Mirnawati Salampe6, Firzan Nainu5, Mayeen Uddin Khandaker7, Abubakr M Idris8,9, Jesus Simal-Gandara10.
Abstract
In the past few years, phytochemicals from natural products have gotten the boundless praise in treating cancer. The promising role of cruciferous vegetables and active components contained in these vegetables, such as isothiocyanates, indole-3-carbinol, and isothiocyanates, has been widely researched in experimental in vitro and in vivo carcinogenesis models. The chemopreventive agents produced from the cruciferous vegetables were recurrently proven to affect carcinogenesis throughout the onset and developmental phases of cancer formation. Likewise, findings from clinical investigations and epidemiological research supported this statement. The anticancer activities of these functional foods bioactive compounds are closely related to their ability to upregulate p53 and its related target genes, e.g., p21. As the "guardian of the genome," the p53 family (p53, p63, and p73) plays a pivotal role in preventing the cancer progression associated with DNA damage. This review discusses the functional foods bioactive compounds derived from several cruciferous vegetables and their use in altering the tumor-suppressive effect of p53 proteins. The association between the mutation of p53 and the incidence of gastrointestinal malignancies (gastric, small intestine, colon, liver, and pancreatic cancers) is also discussed. This review contains crucial information about the use of cruciferous vegetables in the treatment of gastrointestinal tract malignancies.Entities:
Keywords: apoptosis; cruciferous vegetables; foods bioactive compounds; gastrointestinal cancer; p53 family
Year: 2022 PMID: 35990357 PMCID: PMC9386315 DOI: 10.3389/fnut.2022.951935
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Macronutrients of cruciferous vegetables per 100 g.
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
| var. | Broccoli | 34 | 89.30 | 6.64 | 2.82 | 0.37 | 2.60 |
| var. | Brussels sprouts | 43 | 86 | 8.95 | 3.38 | 0.30 | 3.80 | |
| var. | Cabbage | 25 | 92.18 | 5.80 | 1.28 | 0.10 | 2.50 | |
| var. | Cauliflower | 25 | 92.07 | 4.97 | 1.92 | 0.28 | 2.00 | |
| var. | Collard greens | 32 | 89.62 | 5.42 | 3.02 | 0.61 | 4.00 | |
| var. | Kale | 35 | 89.63 | 4.42 | 2.92 | 1.49 | 4.10 | |
|
| var. | Mustard greens | 27 | 90.70 | 4.67 | 2.86 | 0.42 | 3.20 |
|
| ssp. | Turnip | 28 | 91.87 | 6.43 | 0.90 | 0.10 | 1.80 |
| ssp. | Rapini, broccoli rabe | 22 | 92.55 | 2.85 | 3.17 | 0.49 | 2.70 | |
|
| - | Radish | 16 | 95.30 | 3.40 | 0.70 | 0.10 | 1.60 |
Micronutrients of cruciferous vegetables per 100 g.
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Broccoli | Inflorescence | 316 | 47 | 21 | 0.7 | 89.2 | 63 |
| Brussels sprouts | Buds | 389 | 42 | 23 | 1.4 | 85 | 61 |
| Cabbage | Leaves | 170 | 40 | 12 | 0.5 | 36.6 | 43 |
| Cauliflower | Inflorescence | 299 | 22 | 15 | 0.4 | 48.2 | 57 |
| Collard greens | Leaves | - | 232 | 27 | - | 35.30 | - |
| Kale | Leaves | 491 | 150 | 47 | 1.5 | 120 | 141 |
| Mustard greens | Leaves | 384 | 115 | 32 | 1.64 | 70 | 12 |
| Turnip | Root | 191 | 30 | 11 | 0.3 | 21 | 15 |
| Rapini, broccoli rabe | Leave, stem, flower buds | - | 108 | 0.39 | - | 20.20 | - |
| Radish | Root | 233 | 25 | 10 | 0.3 | 14.8 | 25 |
Figure 1Enzymatic hydrolysis pathways of glucosinolate.
Figure 2Chemical structures of glucosinolate and their breakdown products.
Figure 3Carotenoids present in cruciferous vegetables.
Figure 4Phenolic compounds present in cruciferous vegetables.
Several common codons that are vulnerable to cellular stress leading to missense mutations (68).
|
|
|
|
|---|---|---|
| 5 (175) | Guanine → Adenine | Arginine → Histidine |
| 7 (245) | Guanine → Adenine | Glycine → Serine |
| Guanine → Adenine | Glycine → Aspartic acid | |
| 7 (248) | Cytosine → Thymine | Arginine → Tryptophan |
| Guanine → Adenine | Arginine → Glutamine | |
| 8 (273) | Cytosine → Thymine | Arginine → Cysteine |
| Guanine → Adenine | Arginine → Histidine | |
| 8 (282) | Cytosine → Thymine | Arginine → Tryptophan |
Figure 5Functional foods bioactive compounds from cruciferous vegetables targeting p53 Family in gastrointestinal tract and associated cancers.
Functional ingredients from cruciferous vegetables in gastrointestinal tract and associated cancers.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Gastric cancer | Curcumin | 50–100 μM | Efficient chemo sensitizing effect and also inhibits viability, proliferation, and migration of gastric cancer cells mainly | ( | |
| Quercetin | Human model | 3.89–6.02 mg/day | Inhibited cell growth and induced apoptosis, necrosis, and autophagy | ( | |
| Allicin | 15–120 μg/ml | Apoptotic activity | ( | ||
| β-carotene | Human cell line | 0–6.2 μg/dl | Reduced risk of gastric cancer | ( | |
| Isothiocyanate | Human model | 0.1 μmol/L. | Effective in protecting against gastric cancer, particularly among those who were lack of genes GSTMI (glutathione S-transferase M1) and GSTTI (glutathione S-transferase T1) | ( | |
| Sulforaphane | Gastric cancer stem cells (CSCs) | 0, 1, 5, 10 μM | Inhibitory action of sulforaphane on gastric CSCs | ( | |
| Thioredoxin reductase (TR) | Human model | 7.34 U/mL | Threshold of TrxR activity was distinctive in the diagnosis of different tumor types | ( | |
| Astaxanthin | Human gastric adenocarcinoma cell lines (AGS, KATO-III, MKN-45, and SNU-1) | 0, 10, 50, and 100 μM | Astaxanthin inhibits proliferation by interrupting cell cycle progression in KATO-III and SNU-1 gastric cancer cells | ( | |
| Benzyl isothiocyanate | AGS human gastric cancer cells | 0, 0.25 and 0.5 mM | Inhibit migration and invasion of human gastric cancer AGS cells | ( | |
| Small Intestine cancer | Phenyl isothiocyanate | Human model | 0.2–25 mmol/L | Isothiocyanate exposure may reduce the risk of colorectal cancer | ( |
| Thioredoxin reductase (TR) | Human model | - | Controls cell development by providing the reducing power for p53 and the redox cycling of endogenous antioxidants | ( | |
| Sulforaphane | GC cell lines | 0–22.5 μM | Role in p53 stabilization and nuclear localization | ( | |
| Astaxanthin | Small intestine carcinoma cell lines | 0, 10, 50, and 100 μM | Interrupting cell cycle progression | ( | |
| Curcumin | Mice model | 1,000 mg/kg | Suppressed Nrf2-Dependent Genes in Small Intestine | ( | |
| Quercetin | Mice model | 2% in diet | Anti-tumor activity in the small intestine | ( | |
| Benzyl isothiocyanate (BITC) | Rat Model | 400 P.P.M | Promising chemopreventive agents for human intestinal neoplasia | ( | |
| Sulforaphane | Mice model | 300 and 600 p.p.m. | Developed significantly less and smaller polyps with higher apoptotic and lower proliferative indices in their small intestine | ( | |
| Colon cancer | Isothiocyanate | Colon cancer cell lines | 2.5 mM | Block the (PI3K)/AKT-dependent survival pathway of colon cancer cell lines, while stimulating the p53 pathway | ( |
| BITC | HCT-116 cells | 50 μM | Capable of ameliorating the inflammation associated with colon cancer | ( | |
| Sulforaphane | HCT116 colon cancer cells | DNA repair protein causes DNA damage in colon cancer cells | ( | ||
| PEITC | HT29 colon cancer cells | 10–50 μM | Have anti-metastatic and anti-inflammatory effects against colon cancer | ( | |
| 3,3′-diindolylmethane (DIM) | Colon cancer HT29 cells | 100 μM | Cytotoxic effects | ( | |
| β-carotene | Human models | - | Increase Bax and P53 levels in malignant colon cells while decreasing Bcl-2 levels | ( | |
| Astaxanthin | HCT-116 colon cancer cells | 5–25 μg/ml | Increase of p53, p21WAF-1/CIP-1 and p27 expression (220, 160, 250%, respectively) was observed, concomitantly with a decrease of cyclin D1 expression (58%) and AKT phosphorylation (21%). | ( | |
| Bixin | CRC cell lines | 0-80 μM | Inhibit the CRC cell proliferation and survival | ( | |
| β-cryptoxanthin | Human models | - | Enhances the antitumoral activity of oxaliplatin through δnp73 negative regulation in colon cancer | ( | |
| Lycopene | Colon cancer HT-29 cells | 2, 5, 10 μM | Inhibited cell proliferation in human colon cancer HT-29 cells | ( | |
| Hepatic and Pancreatic cancer | Bixin | Hep3B cell | 5-50 μg/ml | Cell growth inhibition | ( |
| Quercetin | PANC-1 | 0, 10, 25, 50, 100, or 200 μM | Shows significant pro-apoptotic effects | ( | |
| Curcumin | Hepatic cancer human models | - | Inhibited MMP-9 secretion in HCC (CBO140C12) cells, and repressed the adhesion and migration of fibronectin and laminin | ( | |
| β-cryptoxanthin | Human models | - | Decreased significantly with increased prevalence of Leiden mutation (as a genetic factor) in patients before the clinical manifestation of histologically different GI cancer | ( | |
| Lycopene | Hep3B human hepatoma c | - | Induced G0/G1 arrest and S phase block and inhibited cell growth in a dose-dependent manner by almost 40% | ( | |
| Astaxanthin | HepG2 hepatoma cells | 25 and 42 μM | Arrest induction at G0/G1 phase | ( | |
| Fucoxanthin | Mice models | 488.8 mg Fx/kg bw | Mediates the suppression of the CCL21/CCR7 axis, BTLA, tumor microenvironment, epithelial mesenchymal transition, and adhesion | ( | |
| Isothiocyanate sulforaphane | MIA PaCa-2 and PANC-1. | 10 μmol/L sulforaphane. | Sulforaphane Suppressed Growth and Triggered Activation of Caspase-3- and Caspase-8-Dependent Cell Death | ( | |
| BITC | Mice model | 0.5 μmol/L in plasma | BITC-treated mice showed 43% less tumor growth | ( |